Drug research

ABP-450

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as prabotulinumtoxinA

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical DystoniaNCT04871451	AEON	Phase 2	Completed	2023-07-24Actual
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine PreventionNCT05016661	AEON	Phase 2	Terminated	2024-07-31Actual
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical DystoniaNCT04849988	AEON	Phase 2	Completed	2022-07-11Actual
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in AdultsNCT04845178	AEON	Phase 2	Completed	2024-06-19Actual

AEONCompletedPrimary completion: 2023-07-24 · Actual

Trial details

AEONTerminatedPrimary completion: 2024-07-31 · Actual

Trial details

AEONCompletedPrimary completion: 2022-07-11 · Actual

Trial details

AEONCompletedPrimary completion: 2024-06-19 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.